Article
Implementation of BRCA mutations testing in formalin-fixed paraffin-embedded (FFPE) samples of different cancer types.
Pathology, research and practice - 1 Mar 2023
Zannini Giuseppa, Facchini Gaetano, De Sio Marco, De Vita Ferdinando, Ronchi Andrea, Orditura Michele, Vietri Maria Teresa, Ciardiello Fortunato, Franco Renato, Accardo Marina, Zito Marino Federica
Abstract excerpt
BRCA1 and BRCA2 are onco-suppressor genes involved in the DNA repair mechanism. The presence of BRCA1/2 mutations confers a higher risk of developing several cancer types. To date, the FDA approved various PARP inhibitors to treat selected BRCA1/2 mutated oncologic patients. At first, PARP inhibitors were approved for patients with ovarian and breast cancers, and subsequently for metastatic pancreatic...
Topics
Join the communities discussing this publication.